Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
Best 3 Thanksgiving stocks to buy
05:49am, Friday, 24'th Nov 2023
As Thanksgiving festivities wind down and markets remain closed for a two-day hiatus, investors find themselves in a brief respite from the relentless pace of trading.
Eli Lilly and Novo Nordisk Are Big Names in Weight Loss, but Investors Shouldn't Count Out This Healthcare Giant
08:15am, Wednesday, 22'nd Nov 2023
AstraZeneca could pay up to $2 billion to Eccogene for the rights to an obesity drug candidate. That candidate could give patients a safer option than those that are available in the market today.
3 No-Brainer Stocks to Buy With $1,000 Right Now
05:21am, Wednesday, 22'nd Nov 2023
Wall Street's major indexes have bounced back and forth between bull and bear markets over the past four years. Volatility invites opportunity for long-term-minded investors.
Here's Why Astrazeneca (AZN) is a Strong Value Stock
11:17am, Tuesday, 21'st Nov 2023
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
5 Growth Stocks to Buy for 2024
10:11am, Monday, 20'th Nov 2023
This article is an excerpt from the InvestorPlace Digest newsletter. To get news like this delivered straight to your inbox, click here.
AstraZeneca: Leading bank tells us why the stock is a core holding
08:23am, Monday, 20'th Nov 2023
Barclays Capital has issued an optimistic assessment of AstraZeneca PLC (LSE:AZN)'s shares, recommending an "overweight" position with a target price of £135, a significant premium to the current ma
3 stocks that crushed earnings estimates and still tanked
06:17am, Monday, 20'th Nov 2023
Stocks that crush their earnings estimates are supposed to go up. However, that's not always the case.
AstraZeneca Is Trying to Make an Ozempic Competitor (Again), but Don't Rush to Buy the Stock
09:53am, Friday, 17'th Nov 2023
AstraZeneca is making another go at developing a medicine like Ozempic. The U.K. pharma giant purchased licensing rights to a candidate in early-stage clinical trials.
AstraZeneca's (AZN) Capivasertib Gets FDA Nod for Breast Cancer
09:46am, Friday, 17'th Nov 2023
AstraZeneca's (AZN) capivasertib gets approval in combination with Faslodex for HR-positive, HER2-negative metastatic breast cancer.
CDC expedites release of more doses of infant RSV drug from Sanofi, AstraZeneca amid shortage
08:44am, Friday, 17'th Nov 2023
The CDC's move to increase availability of Beyfortus, a monoclonal antibody from Sanofi and AstraZeneca, comes as RSV cases rise in some parts of the country.
AstraZeneca gets US sign-off for breast cancer combination
02:46am, Friday, 17'th Nov 2023
AstraZeneca PLC (LSE:AZN) has secured US approval for a new breast cancer treatment, Truqap (capivasertib), to be used in combination with Faslodex (fulvestrant). It brings hope for a specific group
US FDA approves AstraZeneca's breast cancer drug combination
05:18pm, Thursday, 16'th Nov 2023
The U.S. Food and Drug Administration on Thursday approved AstraZeneca's drug capivasertib in combination with an older drug, providing another treatment option for patients with the most common type
CDC releases 77,000 additional doses of Sanofi-AstraZeneca's RSV drug
02:19pm, Thursday, 16'th Nov 2023
The U.S. Centers for Disease Control and Prevention said on Thursday it has released more than 77,000 additional doses of Sanofi and AstraZeneca's respiratory syncytial virus (RSV) drug Beyfortus.
AstraZeneca to learn from latest Imfinzi trial after endpoint not met
04:26am, Tuesday, 14'th Nov 2023
AstraZeneca said a trial of its Imfinzi drug as an early treatment lung cancer immunotherapy treatment administered with chemoradiotherapy (CRT) failed to make a statistically significant difference
AstraZeneca's Imfinzi plus chemoradiotherapy fail main goal in late stage trial
02:17am, Tuesday, 14'th Nov 2023
Drugmaker AstraZeneca said on Tuesday its cancer drug Imfinzi administered with chemoradiotherapy failed to meet its main goal in a late-stage trial to treat unresectable, Stage 3 non-small cell lung
